Unicycive Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Significant Agreements (Details)

Significant Agreements (Details) - USD ($)									1 Months Ended		9 Months Ended	12 Months Ended
Significant Agreements (Details) - USD ($)	Apr. 10, 2023	Mar. 31, 2023	Feb. 01, 2023	Jul. 14, 2022	Feb. 09, 2022	Jan. 06, 2022	Jul. 19, 2021	Jul. 13, 2021	Sep. 30, 2018	Oct. 31, 2017	Sep. 30, 2021	Dec. 31, 2024	Dec. 31, 2023	Feb. 28, 2023	Aug. 31, 2022
Significant Agreements [Line Items]
Agreement due payments										$ 1,650,000
Second clinical trial payment										$ 50,000
Percentage of royalty payment										2.00%
Common stock valued												$ 524,000
Public market capitalization								$ 50,000,000
Anti-dilution shares of common stock (in Shares)												179,413,500	6,126,863
Research and development expenses											$ 2,200,000
Sublicense income percentage											40.00%
Accounts payable or accrued expense													$ 2,000,000
Revision overall budget						$ 2,900,000
Related payments												$ 2,800,000
Prepaid expenses and other current assets												4,806,000	3,698,000
Research related payments	$ 2,900,000	$ 100,000
Milestone payments			$ 3,700,000
Payment amount												$ 6,500,000
Minimum [Member]
Significant Agreements [Line Items]
Royalties percentage				7.00%
Maximum [Member]
Significant Agreements [Line Items]
Royalties percentage				10.00%
Common Stock [Member]
Significant Agreements [Line Items]
Anti-dilution shares of common stock (in Shares)								438,374
Lotus International Pte Ltd [Member]
Significant Agreements [Line Items]
Sublicense income percentage												20.00%
Syneos Health LLC [Member]
Significant Agreements [Line Items]
Research and development expenses							$ 2,300,000
Quotient Sciences Limited [Member]
Significant Agreements [Line Items]
Research and development expenses						$ 3,700,000
Spectrum Pharmaceuticals, Inc. [Member]
Significant Agreements [Line Items]
Issued of common shares (in Shares)									313,663
Common stock valued									$ 4,000
Public market capitalization									$ 50,000,000
Sublicense income percentage											20.00%
Altair Nanomaterials, Inc [Member]
Significant Agreements [Line Items]
Required to pay											$ 200,000
Altair [Member]
Significant Agreements [Line Items]
Required to pay											$ 4,500,000
Quotient Sciences Limited [Member]
Significant Agreements [Line Items]
Related payments												$ 2,800,000
Prepaid expenses and other current assets													600,000
CBCC Global Research Inc [Member]
Significant Agreements [Line Items]
Research and development expenses					$ 1,400,000
Initial agreement amount		400,000
Research related payments		$ 400,000
Inotiv [Member]
Significant Agreements [Line Items]
Prepaid expenses and other current assets													300,000
Payments to related party												2,900,000
Lee’s Pharmaceutical (HK) Limited [Member]
Significant Agreements [Line Items]
Significant payment received				$ 1,000,000
Milestone payments				$ 1,000,000
Oxylanthanum Carbonate [Member]
Significant Agreements [Line Items]
Related payments													2,700,000
Research related payments													$ 2,700,000
Lotus International Pte Ltd [Member]
Significant Agreements [Line Items]
Significant payment received			$ 700,000
Shilpa Medicare Ltd [Member]
Significant Agreements [Line Items]
Payment amount												$ 6,500,000
Exclusive license agreement [Member]
Significant Agreements [Line Items]
Agreement due payments										$ 50,000
Sublicense Development Agreement [Member]
Significant Agreements [Line Items]
Significant payment received														$ 700,000	$ 1,000,000
Investment [Member] \| Spectrum Pharmaceuticals, Inc. [Member]
Significant Agreements [Line Items]
Interest on ownership									4.00%